All In Biotech

Drug Trial Radar · NCT00329745

Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)

A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants.

Last checked: Nov 19, 2026Latest source record: Dec 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,687 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,687

Actual

Start

Jan 2007

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 2 years, up to 3 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Year 3 extension of the main study rota-028, 029 or 030 is conducted to evaluate vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during third year of life in infants previously vaccinated with human rotavirus (HRV) vaccine or placebo in the following schedules: at 3 and 4 months of age in study rota-028; at 2 and 4 months of age in study rota-029 or rota-030. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Conditions

  • Infections, Rotavirus

Interventions

  • Rotarix™Biological

    Oral administration, 2 doses

  • PlaceboBiological

    Oral administration, 2 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus StrainsTime frame: From Year 2 up to Year 3

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Singapore, Singapore

  • GSK Investigational Site

    Singapore, Singapore

  • GSK Investigational Site

    Singapore, Singapore

  • GSK Investigational Site

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.